Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer

Drug Delivery

Volumn 23, Issue 3, 2016, Pages 968-980

  Ganta, Srinivas ^a   Singh, Amit ^b   Rawal, Yashesh ^c   Cacaccio, Joseph ^a,c   Patel, Niravkumar R ^a   Kulkarni, Praveen ^b   Ferris, Craig F ^b   Amiji, Mansoor M ^b   Coleman, Timothy P ^a,b,c,d  

^a Nemucore Medical Innovations Inc   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c Blue Ocean Biomanufacturing Inc   (United States)

^d Foundation for the Advancement of Personalized Medicine Manufacturing   (United States)

Author keywords

Docetaxel; Folate; Gadolinium; MRI

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DOCETAXEL; DRUG CARRIER; EMULSION; FOLIC ACID; GADOLINIUM; NANOPARTICLE; TAXANE; TAXOID;

ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; EMULSION; FEMALE; HUMAN; MEDICINAL CHEMISTRY; MOUSE; MULTIDRUG RESISTANCE; NUDE MOUSE; OVARIAN NEOPLASMS; PARTICLE SIZE; PROCEDURES; THERANOSTIC NANOMEDICINE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED-RING COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; EMULSIONS; FEMALE; FOLIC ACID; GADOLINIUM; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE; TAXOIDS; THERANOSTIC NANOMEDICINE;

EID: 84958156455     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.923068     Document Type: Article

References (27)

1. Clogston JD, Patri AK. (2011). Detecting and measuring free gadolinium in nanoparticles for MRI imaging. Methods Mol Biol 697: 101-8
2. Ersoy H, Rybicki FJ. (2007). Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis. Journal of Magnetic Resonance Imaging: JMRI 26: 1190-7
3. Fisher RE, Siegel BA, Edell SL, et al. (2008). Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nuclear Med 49: 899-906
4. Ganta S, Singh A, Patel NR, et al. (2014a). Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res
5. Ganta S, Talekar M, Singh A, et al. (2014b). Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSci Tech
6. Goren D, Horowitz AT, Tzemach D, et al. (2000). Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 6: 1949-57
7. Grant CW, Karlik S, Florio E. (1989). A liposomal MRI contrast agent: phosphatidylethanolamine-DTPA. Magn Reson Med 11: 236-43
8. Joo WD, Visintin I, Mor G. (2013). Targeted cancer therapy-are the days of systemic chemotherapy numbered? Maturitas 76: 308-14
9. Kelly RJ, Draper D, Chen CC, et al. (2011). A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17: 569-80
10. Lachman L, Liebermann HA, Kanig JL. (1986). The Theory and practice of industrial pharmacy, Philadelphia: Lea & Febiger
11. Leamon CP. (2008). Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 9: 1277-86
12. Leamon CP, Cooper SR, Hardee GE. (2003). Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. Bioconjug Chem 14: 738-47
13. Levchenko TS, Rammohan R, Lukyanov AN, et al. (2002). Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm 240: 95-102
14. Li J, Sausville EA, Klein PJ, et al. (2009). Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 49: 1467-76
15. Mignogna C, Staibano S, Altieri V, et al. (2006). Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 6: 293
16. Muller C, Schibli R, Krenning EP, De Jong M. (2008). Pemetrexed improves tumor selectivity of 111In-DTPA-folate in mice with folate receptor-positive ovarian cancer. J Nucl Med 49: 623-9
17. Parker N, Turk MJ, Westrick E, et al. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binDing assay. Anal Biochem 338: 284-93
18. Penson RT, Oliva E, Skates SJ, et al. (2004). Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106
19. Pusztai L, Wagner P, Ibrahim N, et al. (2005). Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104: 682-91
20. Rose DP, Connolly JM. (1999). Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83: 217-44
21. Ruff P, Vorobiof DA, Jordaan JP, et al. (2009). A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen. Cancer Chemother Pharmacol 64: 763-8
22. Sadurni N, Solans C, Azemar N, et al. (2005). Studies on the formation of O/W nano-emulsions, by low-energy emulsification methods, suitable for pharmaceutical applications. Eur J Pharm Sci 26: 438-45
23. Seiden MV, Swenerton KD, Matulonis U, et al. (2002). A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86: 302-10
24. Spannuth WA, Sood AK, Coleman RL. (2010). Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 10: 431-7
25. Sudimack J, Lee RJ. (2000). Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41: 147-62
26. Thanos CG, Liu Z, Goddard M, et al. (2003). Enhancing the oral bioavailability of the poorly soluble drug dicumarol with a bioadhesive polymer. J Pharm Sci 92: 1677-89
27. Toffoli G, Cernigoi C, Russo A, et al. (1997). Overexpression of folate binDing protein in ovarian cancers. Int J Cancer 74: 193-8